Adaptive Biotechnologies (ADPT) Equity Average (2018 - 2026)

Adaptive Biotechnologies has disclosed Equity Average across 9 years of filings, most recently posting $217.6 million for Q1 2026.

• Equity Average for Q1 2026 came in at $217.6 million, up 10.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $217.6 million (up 10.8% YoY), and the FY2025 annual result was $210.6 million, down 17.52% from the prior year.
• Equity Average came in at $217.6 million for Q1 2026 at Adaptive Biotechnologies, up from $211.6 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $578.7 million in Q1 2022 to a low of $184.9 million in Q2 2025.
• The 5-year median for Equity Average is $291.5 million (2024), against an average of $332.9 million.
• Across the five-year window, Equity Average sank 38.62% in 2024 and gained 10.8% in 2026, its largest moves.
• Adaptive Biotechnologies' Equity Average stood at $476.0 million in 2022, then decreased by 29.62% to $335.0 million in 2023, then slumped by 36.4% to $213.0 million in 2024, then retreated by 0.66% to $211.6 million in 2025, then increased by 2.81% to $217.6 million in 2026.
• The last three Equity Average figures came in at $217.6 million (Q1 2026), $211.6 million (Q4 2025), and $192.0 million (Q3 2025), per Business Quant data.